PeptideDB

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA)

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA)

CAS No.:

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a polypeptide consisting of 11 amino acid (AA)s that
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a polypeptide consisting of 11 amino acid (AA)s that can bind to Na+/K+-ATPase beta-subunit (ATP1B1) and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA enhances the delivery of some large molecules through the skin.

Physicochemical Properties


Molecular Formula C42H65F3N14O18S2
Molecular Weight 1175.17
Related CAS # Transdermal Peptide Disulfide;888486-23-5
Appearance White to off-white solid powder
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro Cells will upregulate the amount of ATP1B1 to preserve function and structure in the presence of Transdermal Peptide Disulfide due to the particular binding of Transdermal Peptide Disulfide to ATP1B1; thus, the expression of ATP1B1 increases. But with time, some Transdermal Peptide Disulfide molecules would enter cells through endocytosis; as a result, ATP1B1 expression would decline. The way Transdermal Peptide Disulfide and ATP1B1 interact modifies not only the expression of ATP1B1, but also where it is located and ultimately the epidermal layer's structure. Inhibitors or competitors may lessen this interaction, which would decrease the amount of macromolecular medications that are delivered via the skin[1].
References

[1]. Role of the Na(+)/K(+)-ATPase beta-subunit in peptide-mediated transdermal drug delivery. Mol Pharm. 2015 Apr 6;12(4):1259-67.


Solubility Data


Solubility (In Vitro) H2O :~100 mg/mL (~85.09 mM)
Solubility (In Vivo) Solubility in Formulation 1: 100 mg/mL (85.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 0.8509 mL 4.2547 mL 8.5094 mL
5 mM 0.1702 mL 0.8509 mL 1.7019 mL
10 mM 0.0851 mL 0.4255 mL 0.8509 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.